China Biologic Products

Hallo, nach meinen Empfehlungen zu der CBP-Aktie (CBPO:USNASDAQ GS China Biologic Products Holdings Inc) konnte nun auch der Anstieg beim Aktienkurs attestiert werden. Die Erlössituation bei CBP ist weiter gestiegen. Umsatz- und operatives Ergebnis sind ebenfalls überdurchschnittlich. Auf Quartalssicht ist auch der Cash-Flow gestiegen. Gruß Daniel

RATING UPDATE! Weiterhin Top Pick! Aussicht positiv. KAUFEN! CHB ist weiterhin top positioniert im asiatischen Markt. Der chinesische Bayer-Konzern punktet mit Umsatz- und Margenstärke. 3Q2017 Total Sales Up 15.1% Net Income Up 14.8% Total Sales Up 15.1% Net Income Up 11.2% 9M 2017 Total Sales Up 10.0% China Biologic Reports BUY!

China Biologic Products' (CBPO) CEO David Gao on Q3 2017 Results - Earnings Call Transcript: Total sales in the third quarter of 2017 increased by 15.1% in both RMB terms and USD terms to $99.6 million from $86.5 million in the same quarter of 2016. The increase was primarily attributable to a sales increase of placenta polypeptide. Sales of IVIG, human rabies immunoglobulin, coagulation factor products and albumin products also increased while sales of human tetanus immunoglobulin decreased. During the third quarter of 2017, human albumin and IVIG products remained the Company's two largest sales contributors, while the revenue contribution from the Company's other products continued to grow. As a percentage of total sales, sales from human albumin and IVIG products decreased to 33.0% and 30.9%, respectively, in the third quarter of 2017 compared to 37.0% and 33.1% in the same quarter of 2016, while sales from placenta polypeptide increased to 15.1% of total sales compared to 9.4% in the same quarter of 2016. The sales volume of human albumin products and IVIG increased by 5.8% and 7.9%, respectively, mainly due to enhanced production volumes in Guizhou Taibang. Quelle: https://seekingalpha.com/article/4120510-china-biologic-products-cbpo-ceo-david-gao-q3-2017-results-earnings-call-transcript

-Earnings (Q3): $26.18 Mln. vs. $21.24 Mln. last year. -Earnings Growth (Y-o-Y): 23.3% -EPS (Q3): $0.94 vs. $0.81 last year. -EPS Growth (Y-o-Y): 16.0% -Revenue (Q3): $78.75 Mln vs. $68.92 Mln last year. -Revenue Change (Y-o-Y): 14.3% Read more: http://www.nasdaq.com/article/china-biologic-products-inc-q3-profit-climbs-23-20151103-01605#ixzz3qXjhRn68